PIC Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- PIC Therapeutics's estimated annual revenue is currently $1M per year.
- PIC Therapeutics's estimated revenue per employee is $77,500
Employee Data
- PIC Therapeutics has 13 Employees.
- PIC Therapeutics grew their employee count by 8% last year.
PIC Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head In Vitro Pharmacology | Reveal Email/Phone |
3 | Head In Vitro Pharmacology | Reveal Email/Phone |
4 | Head In Vivo Pharmacology | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Director Business Operations | Reveal Email/Phone |
7 | Chief Development Officer | Reveal Email/Phone |
8 | Chief Medical Officer | Reveal Email/Phone |
PIC Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is PIC Therapeutics?
PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of eukaryotic translation initiation factors (eIFs). PIC Therapeutics, led by President and CEO Dr. Kathy Bowdish, was launched to translate these discoveries into small molecule precision therapeutics to benefit cancer patients. Our precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Our selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
keywords:N/A
N/A
Total Funding
13
Number of Employees
$1M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Natick
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 13 | 8% | N/A |
#2 | $2M | 15 | 0% | N/A |
#3 | $1.3M | 15 | 7% | N/A |
#4 | $1.3M | 17 | 6% | N/A |
#5 | $2.8M | 17 | 13% | N/A |